Methoxyamine hydrochloride - TRACON

Drug Profile

Methoxyamine hydrochloride - TRACON

Alternative Names: Methoxyamine - TRACON; TRC 102; TRC 102 oral solution - TRACON

Latest Information Update: 14 Mar 2017

Price : $50

At a glance

  • Originator TRACON Pharmaceuticals
  • Developer Case Western Reserve University; National Cancer Institute (USA); TRACON Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action DNA repair inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma; Mesothelioma
  • Phase I/II Solid tumours
  • Phase I Non-small cell lung cancer
  • No development reported Lymphoma

Most Recent Events

  • 06 Mar 2017 National Cancer Institute suspends participant recruitment in a phase-I clinical trial in Non-small cell lung cancer (Combination therapy, Late-stage disease) in USA (PO)
  • 27 Jan 2017 Chemical structure information added
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Lymphoma(Combination therapy, Second-line therapy or greater) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top